Interchangeability of 2 diphtheria-tetanus-acellular pertussis vaccines in infancy

Pediatrics

Volumn 109, Issue 4, 2002, Pages 666-672

  Greenberg, David P ^a   Pickering, Larry K ^b   Senders, Shelly D ^c   Bissey, Jeffrey D ^d   Howard, Robert A ^e   Blatter, Mark M ^f   Reisinger, Keith ^f   Pichichero, Michael E ^g   Howe, Barbara J ^h  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b CHILDREN S HOSPITAL OF THE KING S DAUGHTERS   (United States)

^c Dr Shelly Senders and Associates   (United States)

^d The Everett Clinic   (United States)

^e Sciman Biomedical Research   (United States)

^f Primary Physicians Research   (United States)

^g UNIVERSITY OF ROCHESTER   (United States)

^h GLAXOSMITHKLINE   (United States)

Author keywords

Diphtheria tetanus pertussis vaccine; Immunogenicity; Infant; Interchangeability

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS ACELLULAR PERTUSSIS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SAFETY; DRUG SCREENING; ENZYME IMMUNOASSAY; FEMALE; FEVER; HUMAN; IMMUNITY; IMMUNOGENICITY; INFANT; INJECTION PAIN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VACCINATION;

ANTIBODIES; BACTERIAL OUTER MEMBRANE PROTEINS; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HUMANS; INFANT; MALE; SINGLE-BLIND METHOD; VIRULENCE FACTORS, BORDETELLA;

EID: 0036217965     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.109.4.666     Document Type: Article

References (30)

1. Diphtheria, tetanus, and pertussis vaccine: A comparison of the immune response and adverse reactions to conventional and acellular pertussis components
2. Evaluation of a new highly purified pertussis vaccine in infants and children
3. Primary immunization series for infants: Comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids
4. Comparison of 13 acellular pertussis vaccines: Adverse reactions
5. Pertussis vaccination: Acellular pertussis vaccine for the fourth and fifth doses of the DTP series. Update to supplementary ACIP recommendations of the Advisory Committee on Immunization Practices
6. Pertussis vaccination: Use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
7. Notice to readers. FDA approval of a fourth acellular pertussis vaccine for use among infants and young children
8. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis
9. Efficacy of acellular pertussis vaccine in early childhood after household exposure
10. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine
11. Efficacy of a two-component acellular pertussis vaccine in infants
12. A placebo-controlled trial of a pertussis-toxoid vaccine
13. Pertussis
14. Administration of combined diphtheria and tetanus toxoids and pertussis vaccine, hepatitis B vaccine, and Haemophilus influenzae type b (Hib) vaccine to infants and response to a booster dose of Hib conjugate vaccine
15. Acellular pertussis vaccination of 2-month-old infants in the United States
16. Comparison of 13 acellular pertussis vaccines: Overview and serologic response
17. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children
18. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children
19. Immunogenicity of acellular pertussis vaccines using two vaccines for primary immunization
20. Differences in reactogenicity and antigenicity of acellular and standard pertussis vaccines combined with diphtheria and tetanus in infants
21. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants
22. Comparison of diphtheria and tetanus toxoids and bicomponent acellular pertussis vaccine with diphtheria and tetanus toxoids and whole-cell pertussis vaccine in infants
23. Reactogenicity and immunogenicity of a three-component acellular pertussis vaccine administered as the primary series to 2, 4, and 6 month old infants in the United States
24. Comparison of diphtheria-tetanus-2 component acellular pertussis vaccines in United States and Japanese infants at 2, 4, and 6 months of age
25. Acellular pertussis vaccine (Infanrix-DTPa; SB-3): A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection
26. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection
27. A new DTPa-HBV-IPV vaccine co-administered with Hib, compared to commercially available DTPw-IPV/Hib vaccine co-administered with HBV, given at 6, 10, and 14 weeks following HBV at birth
28. Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants
29. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated poliovirus and Haemophilus influenzae type b vaccines given as either separate or mixed injections
30. Equivalence and noninferiority trials